Bucher, Kirsten
Rodríguez-Bocanegra, Eduardo
Wissinger, Bernd
Strasser, Torsten
Clark, Simon J.
Birkenfeld, Andreas L.
Siegel-Axel, Dorothea
Fischer, M. Dominik
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FI 2336/1-1, FI 2336/1-1)
Universitätsklinikum Tübingen
Article History
Received: 9 July 2022
Accepted: 25 January 2023
First Online: 2 February 2023
Competing interests
: M.D.F. is on the advisory board of and/or consulting and/or receiving honoraria/grant money/travel support from following companies: Adelphi Values, Advent France Biotechnology, Alphasights, Arctos, Atheneum, Axiom Healthcare Strategies, Biogen, Decision Resources, Dialectica, Frontera Therapeutics, Janssen Research & Development, Navigant, Novartis, Roche, RegenxBio, Sirion, STZeyetrial. He is director of Fischer Consulting Limited and holds a patent (50%) on a gene therapy product for X-linked Retinitis Pigmentosa. S.J.C. is an inventor on patents describing the use of complement inhibitors for inflammatory disease, and is a co-founder and scientific consultant of Complement Therapeutics, which is developing complement inhibitors for therapeutic purposes including ocular disease. K.B., E.R.B, B.W., T.S., A.L.B. and D.S.-A. declare no potential conflict of interest.